Wells Fargo & Company Immix Biopharma, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMMX
# of Institutions
34Shares Held
4.86MCall Options Held
0Put Options Held
0-
Aigh Capital Management LLC Baltimore, MD1.41MShares$2.08 Million1.01% of portfolio
-
Bleichroeder LP New York, NY850KShares$1.26 Million0.61% of portfolio
-
Cable Car Capital LLC San Francisco, CA796KShares$1.18 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA599KShares$885,8340.0% of portfolio
-
Lynwood Capital Management Inc.405KShares$599,40011.13% of portfolio
About Immix Biopharma, Inc.
- Ticker IMMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,910,100
- Market Cap $20.6M
- Description
- Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specif...